Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Hepatocellular Carcinoma Topic Center

Featured

News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
From Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
Quiz
Your IO Learning: Histotripsy
05/09/2024
Test your knowledge about histotripsy with this installment of Your IO Learning.
Test your knowledge about histotripsy with this installment of Your IO Learning.
Test your knowledge about...
05/09/2024
IO Learning
Osman Ahmed, MD, University of Chicago Medicine
Videos
Histotripsy: Current and Future Applications
05/09/2024

Featuring Osman Ahmed, MD

Featuring Osman Ahmed, MD
Osman Ahmed, MD, gives an overview of histotripsy and explains the recent #HOPE4LIVER trial, looking the safety and efficacy of this technique for liver tumors.
Osman Ahmed, MD, gives an overview of histotripsy and explains the recent #HOPE4LIVER trial, looking the safety and efficacy of this technique for liver tumors.
Osman Ahmed, MD, gives an...
05/09/2024
IO Learning
Christos Georgiades, MD, PhD, Johns Hopkins Hospital
Videos
Physics of Histotripsy
05/09/2024

Featuring Christos Georgiades, MD, PhD

Featuring Christos Georgiades, MD, Ph...
Christos Georgiades, MD, PhD, explains the physics of histotripsy and how this technique differs from existing interventional oncology treatments.
Christos Georgiades, MD, PhD, explains the physics of histotripsy and how this technique differs from existing interventional oncology treatments.
Christos Georgiades, MD, PhD,...
05/09/2024
IO Learning
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
Allison Casey
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
Robert Abraham, MD, FSIR, FRCPC, Dalhousie University
Conference Coverage
Potential of Imageable Glass Y90 Microspheres for Radioembolization Among Patients With Hepatocellular Carcinoma
04/18/2024

Featuring Robert Abraham, MD, FSIR, FRCPC

Featuring Robert Abraham, MD, FSIR, F...
At the 2024 SIR Annual Meeting, Robert Abraham, MD, FSIR, FRCPC, presented safety and efficacy results from a trial evaluating the use of multimodal imageable glass Y90 microspheres (Eye90 microspheres) for radioembolization for patients with...
At the 2024 SIR Annual Meeting, Robert Abraham, MD, FSIR, FRCPC, presented safety and efficacy results from a trial evaluating the use of multimodal imageable glass Y90 microspheres (Eye90 microspheres) for radioembolization for patients with...
At the 2024 SIR Annual Meeting,...
04/18/2024
IO Learning
Kevin P. Henseler, MD, FACR, Midwest Radiology
Conference Coverage
Unique Shear-Thinning Hydrogel Embolic Material Demonstrates Feasibility
04/16/2024

Featuring Kevin P. Henseler, MD, FACR

Featuring Kevin P. Henseler, MD, FACR...
Kevin P. Henseler, MD, FACR, discusses real-world experience with a unique shear-thinning hydrogel embolic material.
Kevin P. Henseler, MD, FACR, discusses real-world experience with a unique shear-thinning hydrogel embolic material.
Kevin P. Henseler, MD, FACR,...
04/16/2024
IO Learning
Daniel B. Brown, MD, FSIR
Videos
Y90 Radioembolization for Patients With Hepatocellular Carcinoma Who Have Undergone Prior Resection
04/12/2024

Featuring Daniel B. Brown, MD, FSIR

Featuring Daniel B. Brown, MD, FSIR ...
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR,...
04/12/2024
IO Learning
Qian (Clark) Yu, MD, University of Chicago
Conference Coverage
Combining Transarterial Radioembolization and Systemic Therapy for Unresectable Cholangiocarcinoma
04/12/2024

Featuring Qian (Clark) Yu, MD

Featuring Qian (Clark) Yu, MD
At the SIR 2024 Annual Meeting, Clark Yu, MD, shared data on the combination of transarterial radioembolization with systemic capecitabine for patients with unresectable cholangiocarcinoma.
At the SIR 2024 Annual Meeting, Clark Yu, MD, shared data on the combination of transarterial radioembolization with systemic capecitabine for patients with unresectable cholangiocarcinoma.
At the SIR 2024 Annual Meeting,...
04/12/2024
IO Learning

Subscribe

IO Learning Newsletter

News

News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
Allison Casey
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
Adding Radiation to Systemic Therapy Extends Overall Survival for Patients with Advanced Liver Cancer
10/24/2022
American Society for Radiation Oncolo...
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial...
10/24/2022
IO Learning
News
New technology aims toward earlier detection of hepatocellular carcinoma
08/04/2022
University of California, Los Angeles (UCLA), Health Sciences Primary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the United States each year. The high mortality rates can be...
University of California, Los Angeles (UCLA), Health Sciences Primary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the United States each year. The high mortality rates can be...
University of California, Los...
08/04/2022
IO Learning
News
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
06/03/2022
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It...
06/03/2022
IO Learning
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
Transit Scientific Announces First Worldwide Case Performed with Innovative Embolic-Delivery Microcatheter
07/09/2024
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press...
07/09/2024
Vascular Disease Management
Imaging Systems
University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients
05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance...
05/08/2024
Cath Lab Digest
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
Allison Casey
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
First-of-Its-Kind Surgical Foam Technology Improves Operating Room Workflow
04/24/2024

Syntervention Press Release

Syntervention Press Release
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina,...
04/24/2024
EP Lab Digest
News
Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management
News
Radiation Therapy May Be Potential Heart Failure Treatment
11/28/2023

Julia Evangelou Strait

Julia Evangelou Strait
The study suggests that low-dose radiation therapy improves heart function, at least in part, by reducing the number of inflammatory immune cells in the heart muscle.
The study suggests that low-dose radiation therapy improves heart function, at least in part, by reducing the number of inflammatory immune cells in the heart muscle.
The study suggests that low-dose...
11/28/2023
Cath Lab Digest
News
Canon Medical Introduces Alphenix Sky 12 HD Interventional System
09/12/2023
Tustin, CA (12 September 2023) — Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD...
Tustin, CA (12 September 2023) — Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD...
Tustin, CA (12 September 2023) —...
09/12/2023
IO Learning

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement